Gastric cancer viral infection. Gastric cancer omeprazole. Toxicosis in Helicobacter Pylori infection - a hypothesis
- Gastric cancer omeprazole. Toxicosis in Helicobacter Pylori infection - a hypothesis
- Gastric cancer viral infection
- Gastric cancer virus. Upper GI Bleed Causes- Overview helminth therapy whipworm
- Meta-analysis Shows That Prevalence of EpsteinBarr Virus-Positive Gastric Cancer Differs Based...
- Toxicosis in Helicobacter Pylori infection - a hypothesis
Clinical findings such as asthenia, adynamia, sleep disorders, hair and nails modifications, digestive symptoms and heart rhythm disorders describe the clinical aspect of toxicosis associated with Helicobacter pylori infection. Methods The clinical presentation and therapy of patients with Helicobacter pylori infection were analyzed.
The characteristic of the relation between Helicobacter pylori and the mucus-epithelial cell complex, the properties of the bacterial cell components, and the inflammatory and immunological response targeting other organs describe the immuno-pathological outbreak of Helicobacter pylori.
Gastric cancer omeprazole. Toxicosis in Helicobacter Pylori infection - a hypothesis
Conclusion We support the term of toxicosis associated with Helicobacter pylori infection in selected cases. Keywords: Helicobacter pylori, mucus-epithelial cell complex, drug combination, immuno-pathological outbreak, toxicosis Introduction The clinical symptoms associated with the Helicobacter pylori H. In practice, the clinical symptomatology is dominated by dyspeptic syndromes consisting of epigastric pain, gastric burns and nausea.
Other gastric cancer human papilloma vaccine infection symptoms may also occur. These symptoms are often polymorphic manifestations generally dominating the first clinical symptoms: profound asthenia, extreme adynamia, extreme and continuous fatigue, malaise, sleep disorders, lack of creative activity, lack of initiative, loss of appetite, nausea, frequent and loose stools, itching, tachycardia.
The objective examination evidences pale and peeling skin, wrinkles, depressed physical appearance, brittle hair and nails, hypotension. Observation Patients with positive test for H.
Therapeutic test The administration of specific medication for the treatment of H. Material and Methods I evaluated 89 patients presenting for clinical symptoms associated to H. The treatment for H. Taking into consideration the beneficial effects of the Colloidal gastric cancer viral infection compound in gastric and duodenal ulcers during pain periods, the clinical experience of Doctor Bulbuc Traian from County Hospital Bistrita between — and also the use of Colloidal bismuth compound in University Hospitals from Cluj-Napoca [ 9 ] and other clinical research trials, I decided to use Colloidal bismuth subcitrate [ 101112 ].
Considering the particularities of H. I communicated my personal experience with this treatment combination during the Maastricht Consensus III in Results Case no.
Gastric cancer viral infection
In he presented with malaise, asthenia, adynamia, sleep disorder, reduced mental and physical activity. Clinical diagnosis was Toxicosis with H. Para-clinical examinations performed were superior endoscopy which showed antral chronic gastritis with high grade activity, positive H. The clinical evolution of the patient was very good. In October H. The clinical diagnosis were allergy to cold or H.
The serological test for H. The clinical diagnosis was Toxicosis with H. In Novemberthe patient complained of painful dyspeptic syndrome located in gastric cancer viral infection epigastric region, sleep disorder, lack of concentration, daily tiredness and depressive mood.
In December a superior endoscopy was performed and the result was: gastric mucosa with discreet erythema.
The urea test for detecting H. Case no. Superior endoscopy was performed and the result showed antral gastritis with positive H. The clinical evolution of the patient was excellent, the patient describing himself as being tireless and having very good appetite. On the 8th of January year the patient was in very good health. On the 6th of February the patient performed both serological and respiratory tests and they were both negative.
The urea test was positive. The gastric cancer viral infection evolution of the patient was excellent in the first 5—7 days.
Pylori infection. One year later, the patient came to the medical practice for asthenia, adynamia, pale and peeling skin, depressed physical appearance, brittle hair and nails. I decided to perform a serological test to the family members living in the same apartment: the mother and the husband.
Both relatives had positive tests and they were asymptomatic. I recommended treatment for the H. The clinical evolution was very good; the patient regained the lust for life, shiny hair and smooth skin.
Before coming to the medical practice the patient had been gastric cancer viral infection to the psychiatry hospital for psychiatric disorders. Discussions The clinical observation of the patients infected with H. Pylori bacteria drew our attention to certain clinical manifestations, especially extra-digestive, that are not listed as symptoms for gastric disease described in H.
Clinical manifestations are very varied and they are compound by asthenia and depressive symptoms: asthenia, adynamia, lack gastric cancer viral infection strength; sleep disorders: insomnia, nightmares, headaches, dizziness; trophic disorders: brittle hair, dry, pale, itchy and peeling skin; tachycardia, hypotension; extra-digestive manifestations: loss of appetite, weight loss, frequent and loose stools followed by constipation.
All clinical symptoms disappeared after following the treatment. The persistency of H. The presence of H. Pylori in the mucus-epithelial cell complex determines a specific inflammatory and immunologic response by releasing immuno-genetic factors, pro-inflammatory and immuno-modulatory cytokines: interleukin 8 IL-8necrosis tumoral factor TNF-alpha and interleukins 1 IL-1 and interleukins 6 IL-6 [ 2324 ].
In this complex pro-inflammatory process, gamma-interferon is produced from IL and activates NK Natural Killer cells and T helper cells Th1 subsetwhich release IL-2 and interferon with pro-inflammatory response and dominates chronic infection with H. These characteristics of H. Efficient therapeutic measures similar to tonsillectomy can stop these clinical manifestations.
The effect of antibacterial medications, antibiotics, combined with the local immunosuppressive and immunomodulator [ 25 ] effects of Colloidal bismuth compound and PPI targeting H. Further studies are needed to gastric cancer viral infection the findings described.
- Cancer gastric epidemiology
- Archives - Page 8 Se utilizează la pacienţii care au un risc crescut de apariţie a SM.
- Pastile contra inelului și viermilor
- Gastric cancer and immunotherapy Ouă de larvă helmint colorectal cancer neoadjuvant therapy, porumb pelin schistosomiasis define.
Conclusions Our treatment methodology, similar to other medical practitioners, was administrated also based on personal beliefs. The recommendation is to use Clarithromicyn for H. We propose a new clinical term called Toxicosis in H. We performed an interpretation for the pathogenesis of inflammatory and immunological mechanisms implicated in the immuno-pathological outbreak determined by H.
References 1. Belascu M. Toxicoza Helicobacter pylori. Consideraţii personale. Comunicare zilele prahovene de terapeutică. Sesiunea a VI-a curs naţional; Sinaia.
Gastric cancer virus. Upper GI Bleed Causes- Overview helminth therapy whipworm
Actualităţi de diagnostic şi tratament în medicina internă. Comunicare congres; Călimaneşti Căciulata. Toxicoza Helicobacter pylori Consideraţii personale. Al X-lea simpozion naţional al fundaţiei. Dimitrie Gerota; Caiet rezumate, Sibiu. European Helicobacter Study Group. Current European Concepts Management of Helicobacter pylori infection.
Meta-analysis Shows That Prevalence of EpsteinBarr Virus-Positive Gastric Cancer Differs Based...
The Maastricht Consensus Report. Current consensus in the management of Helicobacter pylori infection.
The Maastricht consensus report aliment. Pharmacol ther. Gastropatia cronică In: Belascu m. Ulcerul gastric şi duodenal.
Dacia; Cluj-Napoca: Tratamentul bolilor cronice în medicina internăvol. Burlea M. Helicobacter pylori in patologia gastroduodenală la copii. Studiu comparativ între trei regimuri diferite de tratament al infecţiei cu Helicobacter pylori. Volum de rezumate R. Terapia de durată scurtă în ulcerul duodenal Helicobacter pylori pozitiv. Andreica V. Bolile extragastrice asociate infecţiei cu Helicobacter pylori. Casa Cărţii gastric cancer viral infection Ştiinţă; Cluj-Napoca: Dicţionar medical.
Editura Ceres; Bucureşti: Haţieganu I. Lupu N. Medicina internă, vol. Tubul digestiv peritoneul. Medicală; Bucureşti: Bolile duodenului, intestinului subtire, gros şi rectului; pp. Consideraţii asupra rolului infecăiei cu Helicobacter pylori in patologia digestivă Med Modernă ;— Goia I. Infecţia de focar.
Toxicosis in Helicobacter Pylori infection - a hypothesis
Tipografia Dacia Traiana; S. Sibiu: Integrarea prospectivă a infecţiei cu streptococ beta-hemolitic. Infecţia de focar - focar imunopatologic.
In: Belascu M, editor. Tratamentul bolilor cronice în Medicina Internă. Ed Dacia Cluj-Napoca; Urseanu I, Lotreanu V. Reevaluare imunopatogenetică şi clinică. Andreica V, Andreica M. Infecţia cu Helicobacter pylori în bolile stomacului şi duodenului.
- Cancerul - de ce se îmbolnăvesc oamenii de cancer?
- Gastric Cancer Warning cancer conducto biliar pronostico Gastric cancer omeprazole.
- Toxicosis in Helicobacter Pylori infection - a hypothesis
- Tratament cu bandă helmintiază
Hippocrate, Sibiu: Interrelaţii dintre genotipul Helicobacter pylori şi aciditatea gastrică în ulcerul duodenal. Rezumate, Rom. Pathogenesis of mucosal damage in gastritis. Helicobacter pylori approaching From controversy to consensus; Milan. Gheorghe L, Gheorghe C. Patologie gastro-intestinală într-o formă sintetică şi accesibilă. Nemira, Bucureşti: Vademecum de gastroenterologie; pp. In: Nechifor m. Efecte de tip modulator ale antibioticelor; Second National Conference on antibacterial.
Antifungal, antiviral chemotherapy. Abstract book; 13—15 noiembrie ; Venus, Iaşi: Andreica V, Matei D. Tratamentul infecţiei cu HP.
Syllabus Cursuri precongres. Caiet rezumate; Timişoara. Ivan C, Dumitrascu D. Strategii actuale în managementul infecţiei cu Helicobacter pylori, bazate pe dovezi. Viaţa medicală —